Fat Loss & Metabolism
Mazdutide
IBI362 · LY3305677 · oxyntomodulin analog
What it is
Mazdutide is a dual GLP-1/glucagon agonist developed by Innovent Biologics (China) and licensed from Eli Lilly. Approved in China in 2025 for obesity. Like other dual agonists, it combines GLP-1's appetite suppression with glucagon's energy expenditure effects.
How it works
Engineered analog of natural oxyntomodulin (a gut hormone that hits both GLP-1 and glucagon receptors). Modified for long half-life and once-weekly dosing.
Benefits
- Up to ~16% body weight loss (Chinese Phase 3 trials)
- Strong glycemic control
- Liver fat reduction
- Approved in China — accessible in some markets
Timeline
- Week 1–4
- Appetite suppression; common nausea.
- Week 24
- 10–14% body weight loss.
- Week 48
- Peak ~16%.
Dosing & titration
Standard dose3–9 mg subQ once weekly
TitrationStandard slow weekly increases
When to titrate upLimited US availability; mostly accessible through Asia-based pharmacies.
Side effects & risks
- Standard GLP-1 side effects
- Limited Western trial data
- Approval based on Chinese trials only
Approved in China only. US/EU approval pending. Most users access through international pharmacies.
Typical price
$200–$500/moVariable; depends on import source.
Studies
- Search PubMed for mazdutide — PubMed searchLive PubMed search
- Ji L et al. Mazdutide Phase 3 in obese Chinese adults — Pivotal approval data. PubMedLancet, 2025
Educational reference only. Not medical advice.